Retaining Domestic Customers and Capturing Overseas Demand in the Gelatin-Related Business
First written in FY2016. 24 of 41 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-11-10.
1 other company's latest entry also says "Worsened".
- FY2026AdvancedAnnual report
「Profit increased as the company reduced costs by reviewing raw-material origins and countries of supply and improving productivity, in addition to benefiting from increasingly stable raw-material prices. As a result, net sales in the gelatin-related business were ¥12,585 million, down 5.0% year on year, operating income was ¥2,372 million, up 49.3%, and segment profit was ¥2,376 million, up 49.2%.」
Despite lower sales, reviews of raw-material sources and countries of supply and productivity improvements reduced costs, resulting in a 49.2% increase in segment profit. - FY2026-H1AdvancedAnnual report
「Profit increased as the company reduced costs by reviewing raw-material sources and countries of supply and improving productivity, in addition to benefiting from stable raw-material prices. As a result, net sales were ¥6,142 million, down 6.7% year on year, operating income was ¥1,168 million, up 92.9%, and segment profit was ¥1,169 million, up 92.4%.」
Although the gelatin-related business recorded lower sales, cost reductions through reviews of raw-material sources and countries of supply and productivity improvements drove a 92.4% increase in segment profit. - FY2025ReframedAnnual report
「Profitability has improved as a result of phased selling-price revisions and a trend toward lower raw-material prices. However, as competitors have become more aggressive, the company will continue working to reduce costs. It will also strengthen partnerships with overseas contract plants to increase supply volumes and continue building a production system that addresses customer needs through the development of differentiated functional materials and materials for specific applications, including halal products.」
In addition to acquiring domestic customers and overseas demand, the company explicitly identified increasing supply through partnerships with overseas contract plants, developing materials for functional and halal applications, and differentiation as key initiatives. - FY2025-H1WorsenedAnnual report
「Gelatin sales for prepared foods, pharmaceutical applications and care services performed well, but sales for health food capsules declined due to reports of health risks, while gummy sales struggled amid intensified competition. Peptide sales also declined as both domestic and export sales were affected by intensified price competition, incidents involving health risks from health foods and the impact of treated water. Profit declined as procurement prices rose due to the yen's depreciation following the price revisions and its prolonged weakness. As a result, net sales were ¥6,585 million, down 7.4% year on year, operating income was ¥605 million, down 35.3%, and segment profit was ¥607 million, down 35.5%.」
Sales for prepared foods, pharmaceutical applications and care services performed well, but health food capsules, gummies and Peptides struggled due to reports of health risks, intensified competition and the impact of treated water. Higher procurement prices resulting from the yen's depreciation also contributed, and segment profit declined 35.5%. - FY2024AdvancedAnnual report
「The Gelatin division performed well in soft capsule, food and gummy candy applications against a backdrop of normalized economic activity and sustained health consciousness. Although export Peptide sales declined due to price competition, domestic sales performed well, led by health food applications, against a backdrop of strong inbound demand. Profitability had been challenged by higher manufacturing costs, but the effect of phased price revisions helped the operating margin recover to pre-pandemic levels.」
As demand recovered across applications and phased price revisions took effect, the gelatin-related business recorded net sales of ¥13,923 million, operating income of ¥1,597 million and segment profit of ¥1,612 million, with the profit margin recovering to pre-pandemic levels. - FY2024-Q3AdvancedAnnual report
「Although profit margins improved following price revisions, the situation remained uncertain due in part to persistently high raw-material costs and exchange-rate movements on imports. As a result, net sales were ¥10,677 million, up 20.0% year on year, operating income was ¥1,227 million, up 176.7%, and segment profit was ¥1,239 million, up 172.0%.」
Gelatin and Peptides for domestic health food applications and other uses performed well, and price revisions improved profit margins. Although challenges such as persistently high raw-material costs remained, net sales increased 20.0% and segment profit increased 172.0%. - FY2024-Q2AdvancedAnnual report
「Gelatin sales performed well, led by capsule and food applications. Although export Peptide sales declined due to price competition, domestic sales increased as health food applications performed well amid the recovery in inbound demand. Raw-material prices continued to rise, partly due to exchange-rate movements on imports, but profit increased as the company passed on part of the higher costs through selling prices, improving its profit margin. As a result, net sales were ¥7,108 million, up 23.3% year on year, operating income was ¥936 million, up 114.4%, and segment profit was ¥941 million, up 113.4%.」
Gelatin for capsules and food applications and domestic Peptide sales for health food applications performed well. Passing on part of the higher raw-material costs through selling prices resulted in a 23.3% increase in net sales and a 113.4% increase in segment profit. - FY2024-Q1AdvancedAnnual report
「Gelatin sales performed well, led by capsule and food applications. Although export Peptide sales declined due to price competition, domestic sales increased as health food applications performed well amid the recovery in inbound demand. Raw-material prices continued to rise, partly due to exchange-rate movements on imports, but profit increased on the strength of sales. As a result, net sales were ¥3,585 million, up 25.0% year on year, operating income was ¥466 million, up 155.7%, and segment profit was ¥467 million, up 152.5%.」
Gelatin for capsules and food applications and domestic Peptide sales for health food applications performed well, resulting in a 25.0% increase in net sales and a 152.5% increase in segment profit despite continued increases in raw-material prices. - FY2023AdvancedAnnual report
「As a result, net sales in the gelatin-related business were ¥12,263 million, up 18.1% year on year, operating income was ¥693 million, up 22.3%, and segment profit was ¥712 million, up 23.0%.」
Domestic and overseas demand for gelatin and Peptides recovered, and the effect of phased selling-price revisions led to higher sales and profit. - FY2023-Q3Higher sales, but cost increases not fully absorbedAnnual report
「Gelatin sales performed well, led by capsule applications, and Peptide sales progressed steadily in Japan and overseas against a backdrop of global growth in the health food market. However, raw-material prices continued to rise, partly due to exchange-rate movements on imports. Although the company was implementing phased selling-price adjustments, these had not yet fully absorbed the higher costs, and profit increased only marginally. As a result, net sales were ¥8,895 million, up 16.2% year on year, operating income was ¥443 million, up 4.4%, and segment profit was ¥455 million, up 4.8%.」
Strong gelatin and Peptide sales drove a 16.2% increase in net sales. Although phased selling-price adjustments were being implemented, higher raw-material prices could not be fully absorbed, limiting the increase in segment profit to 4.8%. - FY2023-Q2AdvancedAnnual report
「Gelatin sales for capsules and gummies performed well, while Peptide sales remained solid in both domestic and overseas markets against a backdrop of growing health consciousness. As imported raw-material prices continued to rise, partly due to exchange-rate movements on imports, the company implemented phased adjustments to selling prices. As a result, net sales were ¥5,764 million, up 14.8% year on year, operating income was ¥436 million, up 50.3%, and segment profit was ¥441 million, up 48.7%.」
Gelatin for capsule and gummy applications and domestic and overseas Peptide sales remained solid, while the company implemented phased selling-price adjustments in response to higher imported raw-material prices. Net sales increased 14.8% and segment profit increased 48.7%. - FY2023-Q1AdvancedAnnual report
「Gelatin sales for capsules, gummies and prepared foods performed well, while Peptide sales remained solid in both domestic and overseas markets against a backdrop of growing health consciousness. As imported raw-material prices continued to rise intermittently, the company adjusted selling prices. As a result, net sales were ¥2,867 million, up 14.7% year on year, operating income was ¥182 million, up 75.8%, and segment profit was ¥185 million, up 72.7%.」
Gelatin sales across applications and domestic and overseas Peptide sales performed well, and selling prices were adjusted in response to higher imported raw-material prices. Net sales and segment profit both increased. - FY2022AdvancedAnnual report
「As a result, net sales in the gelatin-related business were ¥10,385 million, up 13.9% year on year, operating income was ¥566 million, up 107.1%, and segment profit was ¥579 million, up 108.0%.」
Domestic sales of gelatin and collagen peptides and shipments to North America and other markets increased, and business profit improved significantly from the previous fiscal year despite the impact of soaring raw-material prices. - FY2022-Q3Higher sales, but profitability slowed due to higher imported raw-material costsAnnual report
「Gelatin sales recovered and increased for gummy, prepared-food and capsule applications. Peptide sales also recovered in Japan, led by health food applications against a backdrop of growing health consciousness, while shipments to North America and Southeast Asia increased as a result of overseas expansion initiatives. Profitability nevertheless showed signs of slowing due in part to higher prices for imported raw materials.」
Gelatin sales across applications and domestic and overseas Peptide sales recovered and increased, while profitability showed signs of slowing due to higher imported raw-material prices. - FY2022-Q2RestatedAnnual report
「Domestic Peptide sales increased, led by health food applications, while export shipments to North America, China and Southeast Asia increased as a result of overseas expansion initiatives. Profitability nevertheless remained challenging. As a result, net sales were ¥5,021 million, up 26.5% year on year, operating income was ¥290 million, down 15.9%, and segment profit was ¥296 million, down 14.4%.」
Domestic sales for health food applications and overseas shipments to North America, China and Southeast Asia increased, but profitability remained challenging, resulting in higher net sales alongside lower segment profit. - FY2022-Q1Higher sales, but overseas expansion progressed while profitability remained challengingAnnual report
「Domestic Peptide sales increased, led by health food applications. Export shipments to North America, China and Southeast Asia increased as a result of overseas expansion initiatives, but profitability remained challenging. As a result, net sales were ¥2,501 million, up 36.7% year on year, operating income was ¥103 million, down 34.3%, and segment profit was ¥107 million, down 32.3%.」
Domestic sales for health food applications and shipments to North America, China and Southeast Asia increased, resulting in a 36.7% increase in net sales. Profitability remained challenging, however, and segment profit declined 32.3%. - FY2021WorsenedAnnual report
「The Peptide division struggled with domestic sales due to the collapse in inbound demand. Export sales also faced profitability challenges as price competition for collagen peptides intensified amid a decline in overseas economic activity caused by the spread of infectious diseases, despite efforts to maintain market share. As a result, net sales in the gelatin-related business were ¥9,119 million, down 8.5% year on year, operating income was ¥273 million, down 68.7%, and segment profit was ¥278 million, down 68.5%.」
The gelatin-related business recorded lower sales and a sharp decline in profit due to the disappearance of inbound demand, weaker overseas economic activity and price competition. - FY2021-Q3WorsenedAnnual report
「Gelatin sales for gummies and prepared foods remained weak as lifestyles changed due to the COVID-19 pandemic. The Peptide business also struggled because of a sharp decline in inbound demand in Japan. As a result, net sales were ¥6,393 million, down 12.9% year on year, operating income was ¥421 million, down 39.5%, and segment profit was ¥425 million, down 39.6%.」
Gelatin and Peptide sales remained weak and the businesses continued to struggle amid changing lifestyles and a sharp decline in inbound demand. Segment profit fell 39.6% year on year. - FY2021-Q2WorsenedAnnual report
「Gelatin sales for gummies, capsules and prepared foods all remained weak as consumer activity stagnated due to the COVID-19 pandemic. The Peptide business also struggled as inbound demand in Japan declined and export sales fell sharply. As a result, net sales were ¥3,969 million, down 20.5% year on year, operating income was ¥345 million, down 28.2%, and segment profit was ¥347 million, down 28.6%.」
In the gelatin-related business, net sales, operating income and segment profit fell below the same quarter of the previous year due to stagnant consumer activity, lower inbound demand and a sharp decline in export sales. - FY2021-Q1COVID-19 reduced demand, resulting in lower sales and profitAnnual report
「Gelatin sales for gummies, capsules and prepared foods all remained weak as consumer activity stagnated due to the COVID-19 pandemic. The Peptide business also struggled as inbound demand in Japan collapsed and export sales declined. As a result, net sales were ¥1,829 million, down 28.2% year on year, operating income was ¥157 million, down 35.4%, and segment profit was ¥158 million, down 35.6%.」
In the gelatin-related business, net sales and segment profit fell below the same quarter of the previous year due to stagnant consumer activity, a sharp decline in inbound demand and lower export sales. - FY2020AdvancedAnnual report
「The new collagen peptide plant was completed and began operating in August 2019, and the company is working to manufacture and develop higher-value-added products. As a result, net sales in the gelatin-related business were ¥9,970 million, up 0.4% year on year, operating income was ¥875 million, up 1.6%, and segment profit was ¥883 million, up 1.5%.」
The new collagen peptide plant was completed and began operating in August 2019, and the company shifted to manufacturing and developing higher-value-added products. The gelatin-related business increased profit, helped by easing shortages of fish-based raw materials and price revisions. - FY2020-Q3AdvancedAnnual report
「Gelatin sales for capsule applications performed well, but imports and sales declined sharply as pigskin prices rose due to African swine fever in China. Shortages of fish-based raw materials for collagen peptides were easing, and sales for health food and pharmaceutical applications in Japan performed well. The new plant also began production, and the company started manufacturing and developing higher-value-added products. As a result, net sales were ¥7,344 million, down 0.6% year on year, operating income was ¥697 million, up 12.7%, and segment profit was ¥703 million, up 13.7%.」
As shortages of fish-based raw materials began to ease, the new collagen peptide plant started production and the company began manufacturing and developing higher-value-added products. Segment profit increased 13.7%. - FY2020-Q2AdvancedAnnual report
「Gelatin sales increased as sales for capsule and prepared-food applications remained solid. Although shortages of fish-based raw materials continued, Peptide sales for health food and pharmaceutical applications performed well. The company also continued to improve profitability by implementing phased price revisions for fish-derived products. As a result, net sales were ¥4,992 million, up 2.8% year on year, operating income was ¥481 million, up 21.9%, and segment profit was ¥485 million, up 23.0%.」
Despite continued shortages of fish-based raw materials, sales for capsules and prepared foods and Peptide sales for health food and pharmaceutical applications performed well, while phased price revisions for fish-derived products progressed. Net sales increased 2.8% and segment profit increased 23.0%. - FY2020-Q1AdvancedAnnual report
「For fish-derived products, the company is implementing phased price revisions to improve profitability. As a result, net sales were ¥2,547 million, up 2.4% year on year, operating income was ¥244 million, up 12.9%, and segment profit was ¥246 million, up 13.9%.」
The company implemented phased price revisions for fish-derived products, resulting in higher net sales and profit in the gelatin-related business. - FY2019ReframedAnnual report
「In the gelatin-related business, the company will diversify its raw-material sourcing regions to ensure a stable supply of low-cost raw materials, while also diversifying the fish species used as raw materials. To address the expanding collagen market, it will work more closely with its manufacturing and research and development divisions to develop new selling points and further differentiate its products from those of competitors.」
In addition to developing existing customers and capturing overseas demand, the company identified diversification of raw-material sourcing regions and fish species, together with differentiation through collaboration between manufacturing and research and development, as key initiatives. - FY2019-Q3Tight supplies of fish-derived raw materials and limited penetration of price revisionsAnnual report
「Sales of collagen peptides continued to perform well, but fish-derived products remained subject to excess demand in Japan and overseas. Supplies of fish-derived raw materials were tight, and prices continued to rise without any sign of easing. Although the company was implementing price revisions for fish-derived products, they had yet to gain sufficient market acceptance.」
Sales of collagen peptides performed well, while excess demand for fish-derived products led to tight raw-material supplies and continued price increases. Although price revisions are being implemented, they have not yet been fully reflected in selling prices. - FY2019-Q2Profit decline continues despite strong demand due to higher raw-material costsAnnual report
「The Peptide business performed well in Japan and overseas against a backdrop of buoyant health food markets, but production costs for fish-derived products rose as raw-material shortages drove prices higher. As a result, net sales were ¥4,857 million, up 2.1% year on year, while operating income and segment profit were ¥394 million, down 39.4%.」
Demand for health foods in Japan and overseas was strong and net sales increased, but production costs rose due to shortages and higher prices for raw materials used in fish-derived products, resulting in lower profit. - FY2019-Q1Profit declined despite strong demand due to raw-material shortagesAnnual report
「The Peptide business performed well in Japan and overseas against a backdrop of buoyant health food markets, but manufacturing costs rose as raw-material shortages caused prices to surge. As a result, net sales were ¥2,487 million, up 2.5% year on year, while operating income and segment profit were ¥216 million, down 40.4%.」
Demand for Peptides was strong against a backdrop of health food markets in Japan and overseas, but higher manufacturing costs resulting from raw-material shortages and price increases caused profit to decline 40.4% despite higher net sales. - FY2018AdvancedAnnual report
「Although sales of gelatin for prepared foods, mainly through convenience stores, declined, sales for health food soft capsules and gummy candies remained solid. The Peptide division performed well in both Japan and overseas, as collagen regained attention after being featured on a Japanese television program and awareness of collagen increased in overseas markets, particularly Southeast Asia. As a result, net sales in the gelatin-related business were ¥9,521 million, up 11.3% year on year.」
Although sales for prepared-food applications declined, sales for soft capsules and gummies and Peptide sales in Japan and overseas increased, resulting in an 11.3% increase in net sales. The company is making progress in capturing demand for health foods, including in Southeast Asia. - FY2018-Q3AdvancedAnnual report
「Gelatin for prepared foods and gummies remained firm, while health food collagen and peptides performed well both in Japan and overseas. As a result, revenue was ¥6,966 million, up 9.3%, while operating profit and segment profit were ¥889 million, up 6.7%.」
Gelatin for prepared foods and gummies, along with collagen peptides for health foods in Japan and overseas, performed well, driving a 9.3% increase in net sales and a 6.7% increase in both operating income and segment profit. - FY2018-Q2AdvancedAnnual report
「Gelatin for prepared foods and gummies remained firm, while health food collagen and peptides performed well both in Japan and overseas. As a result, revenue was ¥4,755 million, up 15.5%, while operating profit and segment profit were ¥651 million, up 27.5%.」
Gelatin for prepared foods and gummies, and health food collagen and peptides in Japan and overseas, performed well, increasing revenue 15.5% and operating profit and segment profit 27.5%. - FY2018-Q1AdvancedAnnual report
「Gelatin for prepared foods and gummies remained firm. Health food collagen and peptides also performed well both in Japan and overseas. As a result, revenue was ¥2,428 million, up 17.2%, while operating profit and segment profit were ¥362 million, up 32.6%.」
Gelatin for prepared foods and gummies, and health food collagen and peptides in Japan and overseas, performed well, increasing revenue 17.2% and operating profit and segment profit 32.6%. - FY2017AdvancedAnnual report
「The gelatin division performed well in prepared-food applications, particularly for convenience stores, as well as in health food soft capsules and gummy candies, following a focus on proactive proposal activities. The peptide division also performed well as it focused on overseas sales. As a result, revenue from the gelatin-related business was ¥8,551 million, up 3.2% from the previous fiscal year, while operating profit and segment profit were ¥1,142 million, up 99.7%.」
Through proposal activities and a focus on overseas sales, revenue from the gelatin-related business increased 3.2%, while operating profit and segment profit increased 99.7%. - FY2017-Q3AdvancedAnnual report
「Gelatin for capsules used in supplements and other products performed well, while sales for microwaveable applications also remained firm. Sales of peptides for health foods increased overseas. As a result, revenue was ¥6,374 million, up 3.0%, while operating profit and segment profit were ¥833 million, up 96.8%.」
Growth in capsule gelatin, microwaveable applications and overseas sales of peptides for health foods increased revenue 3.0% and operating profit and segment profit 96.8%. - FY2017-Q2AdvancedAnnual report
「Gelatin for capsules used in supplements and other products performed well, while sales of gelatin for gummies and prepared foods also remained firm. Sales of peptides for health foods increased overseas. The business also benefited from the stronger yen in raw material procurement. As a result, revenue was ¥4,117 million, up 2.7%, while operating profit and segment profit were ¥511 million, up 130.2%.」
Capsule gelatin and overseas sales of peptides for health foods grew, increasing revenue 2.7% and operating profit and segment profit 130.2%. - FY2017-Q1AdvancedAnnual report
「Gelatin for capsules used in supplements and other products performed well, while sales of gelatin for gummies and prepared foods also remained firm. Sales of peptides for health foods increased overseas. As a result, revenue was ¥2,071 million, up 5.1%, while operating profit and segment profit were ¥273 million, up 145.0%.」
Growth in capsule gelatin and overseas sales of peptides for health foods drove revenue and profit in the gelatin-related business above the levels recorded in the same quarter of the previous year. - FY2016First statedAnnual report
「The company will focus on developing customers through proposals for new products in order to further capture firm domestic demand. To capture overseas demand, where growth is expected in health food products, it will pursue active public relations activities, including exhibiting at overseas food trade shows, and work to expand its overseas business.」
The company will expand domestic and overseas sales of gelatin and peptides through proposals for new products, customer development and participation in overseas food trade shows.